Published on 5 Aug 2022 on Benzinga via Yahoo Finance
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases.Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%.A typical ORR associated with whole brain radiotherapy alone can commonly range from 20-45% in published studies.Also Read: Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial.The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials. A maximum tolerated dose (MTD) of 45mg daily combined with radiotherapy was confirmed.Enrolment in the second stage of the study is already underway, and the company currently estimates preliminary data from the second part of the phase I clinical trial in CY2023.Price Action: KZIA shares are up 23.40% at $2.19 during the market session on the last check Friday.
See more from Benzinga